Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antihypertensive Drugs: Direct Renin Inhibitors

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...

Antihypertensive Drugs: Angiotensin II Receptor Blockers

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...

Renal Failure: Dose Adjustments

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...

Renal Drug Clearance: Overview

Renal Drug Clearance: Overview

Renal clearance is a crucial parameter in pharmacokinetics that quantifies the rate at which the kidneys excrete a drug. It represents a constant fraction of the central volume of distribution containing the drug that the kidney eliminates per unit of time.
Renal clearance can be calculated using different methods. One approach is to divide the urinary drug excretion rate by the plasma drug concentration. This method directly measures renal clearance, indicating the kidneys' efficiency in...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The Elusive Search for Optimal Blood Pressure Targets.

Current hypertension reports·2017

Same author

A quarter-dose quadpill for initial treatment of hypertension.

Lancet (London, England)·2017

Same author

SPRINT: To Whom Do the Results Apply?

Journal of the American College of Cardiology·2016

Same author

Blood pressure target values: the saga continues.

European heart journal·2015

Same author

A Call for Appropriate Evidence and Outcomes-Based Use and Measurement of Anticoagulation for Atrial Fibrillation: Moving the Population Towards Improved Health Via Multiple Stakeholders.

Journal of managed care & specialty pharmacy·2015

Same author

LCZ696: the next step in improving RAS inhibition?

Current hypertension reports·2015

Search research articles

Related Experiment Video

Updated: Jun 18, 2026

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

Direct renin inhibition: an update.

Rekha Pinto, Alan H Gradman

Current Hypertension Reports

|November 10, 2009

Summary

Aliskiren, a direct renin inhibitor, effectively lowers blood pressure with good tolerability. It offers additional benefits when combined with other renin-angiotensin-aldosterone system blockers, showing promise in clinical trials.

Area of Science:

Pharmacology
Cardiovascular Medicine
Nephrology

Background:

Aliskiren is the first orally active direct renin inhibitor for hypertension.
It possesses unique properties like sustained effects and good tolerability.
Its mechanism involves blocking the renin-angiotensin-aldosterone system (RAAS).

Purpose of the Study:

To evaluate the efficacy and safety of aliskiren in hypertension.
To explore its effects when combined with other RAAS inhibitors.
To assess its potential benefits in specific patient populations like diabetic nephropathy and heart failure.

Main Methods:

Analysis of clinical trial data involving aliskiren.
Pharmacokinetic and pharmacodynamic studies in animals and humans.

More Related Videos

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Related Experiment Videos

Last Updated: Jun 18, 2026

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Evaluation of aliskiren's impact on intrarenal RAAS and angiotensin II effects.

Main Results:

Aliskiren demonstrates placebo-like tolerability and persistent pharmacologic effects.
Combination therapy with other RAAS inhibitors leads to greater blood pressure reduction.
No evidence of paradoxical blood pressure increases despite elevated plasma renin concentrations.
Aliskiren accumulates in renal tissue, blocking intrarenal RAAS and mitigating angiotensin II effects.
In diabetic nephropathy, aliskiren addition to losartan reduced urinary protein excretion by 20%.
In heart failure, aliskiren reduced brain natriuretic peptide levels when added to RAAS inhibitors.

Conclusions:

Aliskiren is an effective antihypertensive agent with a unique mechanism.
Combination therapy with aliskiren and other RAAS inhibitors provides enhanced blood pressure control.
Aliskiren shows potential benefits in managing diabetic nephropathy and heart failure.
Ongoing trials (ASPIRE HIGHER) will determine long-term clinical benefits.